Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.


Journal

JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160

Informations de publication

Date de publication:
13 09 2022
Historique:
entrez: 13 9 2022
pubmed: 14 9 2022
medline: 16 9 2022
Statut: ppublish

Résumé

The Centers for Disease Control and Prevention estimates that 210 000 children and adolescents younger than 20 years had diabetes as of 2018; of these, approximately 23 000 had type 2 diabetes. Youth with type 2 diabetes have an increased prevalence of associated chronic comorbid conditions, including hypertension, dyslipidemia, and nonalcoholic fatty liver disease. Data indicate that the incidence of type 2 diabetes is rising; from 2002-2003 to 2014-2015, incidence increased from 9.0 cases per 100 000 children and adolescents to 13.8 cases per 100 000 children and adolescents. The US Preventive Services Task Force (USPSTF) commissioned a review of the evidence on screening for prediabetes and type 2 diabetes in asymptomatic, nonpregnant persons younger than 18 years. This is a new recommendation. Children and adolescents younger than 18 years without known diabetes or prediabetes or symptoms of diabetes or prediabetes. The USPSTF concludes that the evidence is insufficient to assess the balance of benefits and harms of screening for type 2 diabetes in children and adolescents. There is a lack of evidence on the effect of screening for, and early detection and treatment of, type 2 diabetes on health outcomes in youth, and the balance of benefits and harms cannot be determined. The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for type 2 diabetes in children and adolescents. (I statement).

Identifiants

pubmed: 36098719
pii: 2796244
doi: 10.1001/jama.2022.14543
doi:

Types de publication

Journal Article Practice Guideline Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

963-967

Commentaires et corrections

Type : SummaryForPatientsIn
Type : CommentIn

Auteurs

Carol M Mangione (CM)

University of California, Los Angeles.

Michael J Barry (MJ)

Harvard Medical School, Boston, Massachusetts.

Wanda K Nicholson (WK)

University of North Carolina at Chapel Hill.

Michael Cabana (M)

Albert Einstein College of Medicine, New York, New York.

David Chelmow (D)

Virginia Commonwealth University, Richmond.

Tumaini Rucker Coker (TR)

University of Washington, Seattle.

Karina W Davidson (KW)

Feinstein Institutes for Medical Research at Northwell Health, Manhasset, New York.

Esa M Davis (EM)

University of Pittsburgh, Pittsburgh, Pennsylvania.

Katrina E Donahue (KE)

University of North Carolina at Chapel Hill.

Carlos Roberto Jaén (CR)

The University of Texas Health Science Center, San Antonio.

Martha Kubik (M)

George Mason University, Fairfax, Virginia.

Li Li (L)

University of Virginia, Charlottesville.

Gbenga Ogedegbe (G)

New York University, New York, New York.

Lori Pbert (L)

University of Massachusetts Medical School, Worcester.

John M Ruiz (JM)

University of Arizona, Tucson.

James Stevermer (J)

University of Missouri, Columbia.

Chien-Wen Tseng (CW)

University of Hawaii, Honolulu.

John B Wong (JB)

Tufts University School of Medicine, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH